CYP2C8 and obesity disorder: Additionally, saroglitazar applies its valuable effects on adipose tissue in a rodent model by limiting diet-induced adipose tissue dysfunction, adipocyte hypertrophy, adipocyte cell damage and extracellular matrix deposition in obesity [31] and coadministration of saroglitazar does not cause clinically relevant drug-drug interaction (as per pharmacokinetic data of diverse CYP2C8 substrates) [32].